Parkinsonism & Related Disorders
Volume 15, Issue 1 , Pages 20-23 , January 2009

Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications

  • Paul S. Foster

      Affiliations

    • University of Florida, Gainesville, FL, USA
    • Malcom Randall VAMC, Gainesville, FL, USA
    • Psychology Department, Middle Tennessee State University, 1500 Greenland Drive, Murfreesboro, TN 37132, USA
    • Corresponding Author InformationCorresponding author. Psychology Department, Middle Tennessee State University, 1500 Greenland Drive, Murfreesboro, TN 37132, USA. Tel.: +1 615 898 2007; fax: +1 615 898 5027.
    • ,
  • Valeria Drago

      Affiliations

    • University of Florida, Gainesville, FL, USA
    • Malcom Randall VAMC, Gainesville, FL, USA
    • Oasi Institute for Research on Mental Retardation and Brain Aging, Troina, EN, Italy
    • ,
  • Frank Skidmore

      Affiliations

    • University of Florida, Gainesville, FL, USA
    • Malcom Randall VAMC, Gainesville, FL, USA
    • ,
  • Barry M. Skoblar

      Affiliations

    • Hunter Holmes McGuire VAMC, Richmond, VA, USA
    • ,
  • Gregory P. Crucian

      Affiliations

    • University of Canterbury, Christchurch, New Zealand
    • Brain Injury Rehabilitation Service, Burwood Hospital, Christchurch, New Zealand
    • ,
  • Kenneth M. Heilman

      Affiliations

    • University of Florida, Gainesville, FL, USA
    • Malcom Randall VAMC, Gainesville, FL, USA

Received 25 July 2007 ,Revised 26 December 2007 ,Accepted 8 February 2008.

References 

  1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427–442
  2. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study. Neurology. 1992;42:1142–1146
  3. Leentjens AFG, Lousberg R, Verhey FRJ. Markers for depression in Parkinson's disease. Acta Psychiatr Scand. 2002;106:196–201
  4. Rajput AH, Pahwa R, Pahwa P, Rajput A. Prognostic significance of the onset mode in parkinsonism. Neurology. 1993;43:829–830
  5. Shulman LM, Taback RLT, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord. 2001;16:507–510
  6. Uitti RJ, Baba Y, Whaley NR, Wszolek ZK, Putzke JD. Parkinson disease: handedness predicts asymmetry. Neurology. 2005;64:1925–1930
  7. Kempster PA, Gibb WRG, Stern GM, Lees AJ. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry. 1989;52:72–76
  8. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990;47:1290–1298
  9. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med. 2001;42:1303–1308
  10. Kumar A, Mann S, Sossi V, Ruth TJ, Stoessl AJ, Schulzer M, et al. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain. 2003;126:2648–2655
  11. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med. 1997;24:415–421
  12. Kumakura Y, Gjedde A, Danielsen EH, Christensen S, Cumming P. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms. J Cereb Blood Flow Metab. 2006;26:358–370
  13. Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJA, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692–698
  14. Martin WRW, Calne DB. Imaging techniques and movement disorders. In:  Marsden CD,  Fahn S editor. Movement disorders 2. London: Butterworths; 1987;p. 4–16
  15. Fross RD, Tsin JKC, McLennan DJ, Schultzer M, Calne DB. Asymmetry in Parkinson's disease. Neurology. 1987;37(Suppl.):320
  16. Lee CS, Schulzer M, Mak E, Hammerstad JP, Calne S, Calne DB. Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology. 1995;45:435–439
  17. Morris PL, Robinson RG, Raphael B, Hopwood MJ. Lesion location and poststroke depression. J Neuropsychiatry Clin Neurosci. 1996;8:399–403
  18. Hanna-Pladdy B, Mendoza JE, Apostolos GT, Heilman KM. Lateralised motor control: hemispheric damage and the loss of deftness. J Neurol Neurosurg Psychiatry. 2002;73:574–577
  19. Heilman KM. A tapping test in apraxia. Cortex. 1975;11:259–263
  20. Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain. 1997;120:75–90
  21. Quencer K, Okun MS, Crucian G, Fernandez HH, Skidmore F, Heilman KM. Limb-kinetic apraxia in Parkinson disease. Neurology. 2007;68:150–151
  22. de la Fuente-Fernandez R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ. Nigrostriatal dopamine system and motor lateralization. Behav Brain Res. 2000;112:63–68
  23. Glick SD, Ross DA, Hough LB. Lateral asymmetry of neurotransmitters in human brain. Brain Res. 1982;18:53–63
  24. Rodriguez M, Castellano MA, Palarea MD. Interhemispheric regulation of dopaminergic ascending systems. Life Sci. 1990;47:377–384
  25. Heilman KM, Barrett AM, Adair JC. Possible mechanisms of anosognosia: a defect in self-awareness. Philos Trans R Soc Lond B Biol Sci. 1998;353:1903–1909
  26. Leritz E, Loftis C, Crucian G, Friedman W, Bowers D. Self-awareness of deficits in Parkinson disease. Clin Neuropsychol. 2004;18:352–361
  27. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on–off phenomenon. J Neurol Neurosurg Psychiatry. 1996;60:634–637
  28. Nutt JG. Pharmacodynamics of levodopa in Parkinson's disease. Clin Exp Pharmacol Physiol. 1995;22:837–840
  29. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol. 1996;39:561–573

PII: S1353-8020(08)00054-0

doi: 10.1016/j.parkreldis.2008.02.006

Parkinsonism & Related Disorders
Volume 15, Issue 1 , Pages 20-23 , January 2009

Article Tools

* Image Usage & Resolution